Asked by: Liz Twist (Labour - Blaydon and Consett)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if she will make an assessment of the relationship between the availability of NHS dental care and (a) adult and (b) children dental health in Blaydon constituency.
Answered by Andrea Leadsom
From June 2021 to June 2023, 1,099,769 adults saw a National Health Service dentist in the North-East and North Cumbria Integrated Care Board (ICB) area. This is equal to 46% of the adult population in the ICB area, and is higher than the national figure, which was 41% over the same period. Furthermore, from June 2022 to June 2023, 323,155 children saw an NHS dentist in the ICB area. This is equal to 54% of the child population in the ICB area, and is also higher than the national figure, which was 53% over the same period.
Asked by: Liz Twist (Labour - Blaydon and Consett)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether she has made an estimate of the number of people accessing perinatal mental health services by NHS inclusion groups since 2017.
Answered by Maria Caulfield
The attached tables show the number of people accessing perinatal mental health services by age, ethnicity and indices of Deprivation deciles from 2019/20 to 2021/22. Data prior to 2019/20 is not included as the analysis of perinatal services did not exist prior to this year and as such would be subject to data quality considerations. Data for 2022/23 is due to be published on 22 February 2024.
Asked by: Liz Twist (Labour - Blaydon and Consett)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if she will make an assessment of the system readiness to introduce whole genome sequencing for newborns as part of the NHS.
Answered by Andrew Stephenson
The Generation Study is a research study that will evaluate the utility and feasibility of screening newborns for a larger number of childhood-onset rare genetic conditions in the National Health Service, using whole genome sequencing. Genomics England are working closely with the UK National Screening Committee (UK NSC) to ensure the research generates the right evidence to inform any potential screening recommendations by the UK NSC and commissioning decisions by the NHS. If the evidence from the study indicates that the use of whole genome sequencing in newborn screening is effective, meets the criteria set by the UK NSC and a positive recommendation is made by the UK NSC, health ministers in the United Kingdom will then decide if this recommendation should be accepted. In the meantime, the UK NSC continues to assess proposals for additional conditions for newborn screening as they are received.
Asked by: Liz Twist (Labour - Blaydon and Consett)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what recent progress has been made on the NHS Generation Study.
Answered by Andrew Stephenson
Genomics England has established a set of four principles to determine which rare genetic conditions should be looked for as part of their research study. In October 2023, Genomics England published a list of over 200 conditions which will be screened for as part of the study. Recruitment to the study is due to begin in early 2024. Genomics England have been working with a group of National Health Service sites who will be among the first to recruit participants.
Asked by: Liz Twist (Labour - Blaydon and Consett)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if she will make an assessment of the adequacy of the capacity of the UK National Screening Committee to review new rare conditions for inclusion in a national newborn heel prick screening programme.
Answered by Andrew Stephenson
The UK National Screening Committee’s (UK NSC) remit was expanded last year to consider targeted, and risk stratified screening proposals, in addition to covering population screening programmes. A recruitment campaign is ongoing to expand capacity to be able to manage the increased volume of work expected. In terms of reviewing the evidence for newborn blood spot conditions the UK NSC has an annual call mechanism where proposals to screen for new topics can be submitted. The annual call for 2024 will open in July.
Asked by: Liz Twist (Labour - Blaydon and Consett)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if her Department will make an assessment of the potential merits of mandating the use of carbon monoxide alarms in all health settings.
Answered by Andrew Stephenson
There are no plans to make an assessment. Guidance on ventilation and air filtration systems in National Health Service facilities is provided in Health Technical Memorandum (HTM) 03-01: Specialised Ventilation for Healthcare Premises. As with all guidance provided on the NHS estate, it is reviewed on an ongoing basis and will be updated to reflect changes in approach to relevant areas. The memorandum is available at the following link:
https://www.england.nhs.uk/wp-content/uploads/2021/05/HTM0301-PartA-accessible-F6.pdf
There is a range of national resources available to promote carbon monoxide safety. This includes guidance on GOV.UK, the NHS website and from the Health and Safety Executive. The UK Health Safety Agency also has a programme of work, much of it delivered in partnership with other organisations, to increase awareness of carbon monoxide exposure risks and help to prevent them.
Asked by: Liz Twist (Labour - Blaydon and Consett)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if his Department will make an assessment of the potential merits of mandating the use of carbon monoxide alarms in all health settings.
Answered by Maria Caulfield
It has not proved possible to respond to the hon. Member in the time available before Prorogation.
Asked by: Liz Twist (Labour - Blaydon and Consett)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, with reference to findings in the All-Party Parliamentary Carbon Monoxide Group's report entitled Prepare, Practice, Protect: Improving Carbon Monoxide Safety in Health and Care Services, published July 2023, what recent assessment he has made of the adequacy of funding for national resources on carbon monoxide funding.
Answered by Maria Caulfield
No recent assessment has been made.
There is a range of national resources available to promote carbon monoxide safety. This includes guidance on GOV.UK, the National Health Service website and from the Health and Safety Executive. The UK Health Security Agency also has a programme of work, much of it delivered in partnership with other organisations, to increase awareness of carbon monoxide exposure risks and help to prevent them.
Asked by: Liz Twist (Labour - Blaydon and Consett)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether he is taking steps with Cabinet colleagues to help (a) prevent and (b) diagnose carbon monoxide poisoning in (i) healthcare settings and (ii) the homes of vulnerable people.
Answered by Maria Caulfield
The UK Health Security Agency (UKHSA) works with national and local stakeholders, public health partners and Government Departments to develop advice and actions which can be taken to improve diagnosis and prevent accidental exposure to carbon monoxide (CO) in healthcare settings and homes, including the homes of vulnerable people.
It has a programme of work to increase awareness and prevent exposure to CO. This includes participating in the cross-Government group on gas safety and carbon monoxide awareness and providing updated and consistent evidence, for example, for medical professionals diagnosing and managing CO poisoning in patients, and during antenatal checks.
UKHSA produces advice for the public on the risks from CO and regularly issues national press releases to raise public awareness of the dangers. In addition, UKHSA has published research quantifying CO exposure in the population, identifying risk factors for exposure and interventions to reduce the risk to the public.
Asked by: Liz Twist (Labour - Blaydon and Consett)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether he has considered the potential merits of taking steps to help prevent the withdrawal of medical (a) products and (b) treatments for rare conditions from the UK market where that withdrawal would leave patients without access to such a product or treatment.
Answered by Will Quince
Companies may decide to stop manufacturing a medicine for several reasons including commercial decisions, manufacturing capacity restraint and production problems. Companies are free to review their portfolios as they think necessary, and the Department has no powers to insist that a company continues to keep a product on the market.
There is a team within the Department that deals specifically with medicine supply problems. It has well-established procedures to deal with medicine shortages and discontinuations, whatever the cause, and works closely with the Medicines and Healthcare products Regulatory Agency, the pharmaceutical industry, NHS England, and others operating in the supply chain to help prevent shortages and to ensure that the risks to patients are minimised when shortages do arise. The team will also communicate management advice to the National Health Service advising clinicians on how to manage medicine supply issues.